Alemtuzumab
- Generic Name
- Alemtuzumab
- Brand Names
- Campath, Lemtrada, MabCampath
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 216503-57-0
- Unique Ingredient Identifier
- 3A189DH42V
- Background
Alemtuzumab is a humanized monoclonal antibody specific to lymphocyte antigens. It is a recombinant DNA-derived humanized monoclonal antibody (Campath-1H) that is directed against the 21-28 kD cell surface glycoprotein, CD52. The Campath-1H antibody is an IgG1 kappa with the human variable framework and constant regions, and complementarity-determining regio...
- Indication
用于烷化剂氟达拉滨（fludarabine）治疗失败的B细胞性慢性淋巴细胞白血病患者；亦可用于复发缓解型多发性硬化症治疗。
- Associated Conditions
- B-Cell Chronic Lymphocytic Leukemia, Kidney Transplant Rejection, Relapsing Remitting Multiple Sclerosis (RRMS), Secondary Progressive Multiple Sclerosis (SPMS), Steroid Refractory Acute Graft Versus Host Disease, T-cell Prolymphocytic Leukemia (T-PLL), Refractory Autoimmune Hemolytic Anemia, Refractory Idiopathic thrombocytopenic purpura
- Associated Therapies
- Conditioning regimens for allogeneic stem cell transplantation therapy
T-Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Hematologic Malignancies
- Conditions
- Interventions
- First Posted Date
- 2008-05-23
- Last Posted Date
- 2016-11-22
- Lead Sponsor
- University of Chicago
- Target Recruit Count
- 204
- Registration Number
- NCT00683046
- Locations
- 🇺🇸
The University of Chicago, Chicago, Illinois, United States
A Phase I Study of Alemtuzumab in Patients With Relapsed Ovarian/Primary Peritoneal Cancer.
- Conditions
- Interventions
- First Posted Date
- 2008-03-18
- Last Posted Date
- 2016-12-02
- Lead Sponsor
- University of Michigan Rogel Cancer Center
- Target Recruit Count
- 3
- Registration Number
- NCT00637390
- Locations
- 🇺🇸
University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States
Campath Maintenance in Chronic Lymphocytic Leukemia
- First Posted Date
- 2008-01-08
- Last Posted Date
- 2015-10-15
- Lead Sponsor
- Northwell Health
- Target Recruit Count
- 12
- Registration Number
- NCT00587847
- Locations
- 🇺🇸
Long Island Jewish Medical Center, New Hyde Park, New York, United States
Reduced Intensity Preparative Regimen Followed by Stem Cell Transplant (FAB)
- Conditions
- Interventions
- First Posted Date
- 2007-12-21
- Last Posted Date
- 2016-05-04
- Lead Sponsor
- Baylor College of Medicine
- Target Recruit Count
- 4
- Registration Number
- NCT00579111
- Locations
- 🇺🇸
Texas Children's Hospital, Houston, Texas, United States
🇺🇸The Methodist Hospital, Houston, Texas, United States
Allogeneic Stem Cell Transplant for Patients With Severe Aplastic Anemia
- Conditions
- Interventions
- First Posted Date
- 2007-12-21
- Last Posted Date
- 2016-04-22
- Lead Sponsor
- Baylor College of Medicine
- Target Recruit Count
- 22
- Registration Number
- NCT00578903
- Locations
- 🇺🇸
The Methodist Hospital, Houston, Texas, United States
🇺🇸Texas Children's Hospital, Houston, Texas, United States
Mismatched Family Member Donor Transplantation for Children and Young Adults With High Risk Hematological Malignancies
- Conditions
- Interventions
- First Posted Date
- 2007-12-03
- Last Posted Date
- 2020-04-14
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 73
- Registration Number
- NCT00566696
- Locations
- 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States
A Pilot Trial With Subcutaneous Alemtuzumab and Oral Fludarabinephosphate for the Determination of Safety, Efficacy and Molecular Profiling for the Prediction of Response
- Conditions
- Interventions
- First Posted Date
- 2007-11-30
- Last Posted Date
- 2017-12-07
- Lead Sponsor
- Arbeitsgemeinschaft medikamentoese Tumortherapie
- Target Recruit Count
- 10
- Registration Number
- NCT00565981
- Locations
- 🇦🇹
Universitätsklinik Innsbruck/ Klinik für Innere Medizin, Innsbruck, Austria
🇦🇹A.ö. Landeskrankenhaus Fürstenfeld, Fürstenfeld, Austria
🇦🇹St. Johanns LK, Salzburg, Austria
Belatacept Post Depletional Repopulation to Facilitate Tolerance
- Conditions
- Interventions
- First Posted Date
- 2007-11-30
- Last Posted Date
- 2020-02-11
- Lead Sponsor
- Allan D Kirk, MD, PhD
- Target Recruit Count
- 40
- Registration Number
- NCT00565773
- Locations
- 🇺🇸
Emory University Hospital, Atlanta, Georgia, United States
🇺🇸The Emory Clinic, Atlanta, Georgia, United States
CFAR Study in Patients With Chronic Lymphocytic Leukemia
- Conditions
- Interventions
- First Posted Date
- 2007-09-06
- Last Posted Date
- 2013-03-04
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 60
- Registration Number
- NCT00525603
- Locations
- 🇺🇸
The University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States
Non-Myeloablative Allogeneic Stem Cell Transplantation
- Conditions
- Interventions
- First Posted Date
- 2007-09-06
- Last Posted Date
- 2011-12-07
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 49
- Registration Number
- NCT00525876
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.